BiotechTube
InveniAI

InveniAI

Guilford, United States· Est.
inveniai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20M

Overview

InveniAI is a private, pre-revenue biotechnology company founded in 2017 and headquartered in Guilford, Connecticut. It operates as an AI/ML platform company, partnering with pharmaceutical and biotech firms to accelerate the identification and validation of novel drug candidates. The company has established several strategic collaborations with industry players like Kyowa Kirin and Shionogi, indicating validation of its technology. Its business model centers on leveraging its AlphaMeld® platform to build a pipeline of partnered and internal programs, primarily targeting chronic inflammatory diseases of the gut.

Chronic Inflammatory Diseases of the Gut

Technology Platform

AlphaMeld®: An AI/ML platform that integrates complex scientific, medical, chemical, and biological data to identify and prioritize novel therapeutic targets and modalities, with a focus on pathways like the gut-brain axis and inflammasome.

Funding History

2
Total raised:$20M
Series A$15M
Seed$5M

Opportunities

The massive inefficiency in traditional drug discovery creates a large addressable market for AI-driven solutions.
Focusing on complex diseases with high unmet need, like chronic inflammatory conditions, offers the potential for significant clinical and commercial impact.
Strategic partnerships provide validation, funding, and a path to market for platform-generated insights.

Risk Factors

The platform may fail to generate clinically successful candidates, validating the AI approach.
Intense competition from other AI-biotechs and large pharma internal efforts threatens market position.
As a private, early-stage company, it faces financial dependency on partnerships and funding rounds.

Competitive Landscape

InveniAI competes in the crowded AI-driven drug discovery sector against well-funded public and private companies like Recursion, Exscientia, and Insilico Medicine. It also competes with internal AI initiatives at large pharmaceutical companies. Differentiation is claimed through its AlphaMeld® platform's specific integration capabilities and its focused application on complex biological pathways like the gut-brain axis.

More companies in AI / Machine Learning →More companies in United States →